Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.9K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.9K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.9K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.0K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.0K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward international collaboration in allergy care - WAO White Book on Allergy 2026 - Introduction.

The World Allergy Organization journal·2026
Same author

The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities.

The World Allergy Organization journal·2026
Same author

Toward equitable and evidence-based care in Hereditary Angioedema: Time for inclusive global guidelines.

The World Allergy Organization journal·2026
Same author

Clinical remission in allergy and clinical immunology practice: State of the art and World Allergy Organization (WAO) call to action.

The World Allergy Organization journal·2026
Same author

World Allergy Organization survey on the diagnosis and management trends of perioperative anaphylaxis.

The World Allergy Organization journal·2026
Same author

Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part II-Guidelines on Oral and Ocular Treatments.

Allergy·2026

Related Experiment Video

Updated: Mar 21, 2026

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

14.7K

Obstructive lung diseases and beta-blockers: Where do we stand?

Helena Pité1, Marisa Braga da Cruz2, Mário Morais-Almeida3

  • 1Allergy Center, CUF Descobertas Hospital and CUF Infante Santo Hospital, Lisbon, Portugal; CEDOC, Chronic Diseases Research Center, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal.

European Journal of Internal Medicine
|May 16, 2016
PubMed
Summary

No abstract available in PubMed .

Keywords:
AsthmaAtrial fibrillationBeta-blockerChronic obstructive pulmonary diseaseCoronary artery diseaseHeart failure

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K
Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling
05:47

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Published on: February 12, 2019

22.3K

Related Experiment Videos

Last Updated: Mar 21, 2026

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

14.7K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K
Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling
05:47

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Published on: February 12, 2019

22.3K